Atea Pharmaceuticals Inc
General ticker "AVIR" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $267.9M
Atea Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -10.7%.
Estimated limits based on current volatility of 2.4%: low 3.19$, high 3.34$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.69$, 4.35$]
- 2024-12-30 to 2025-12-30 estimated range: [1.74$, 4.33$]
Financial Metrics affecting the AVIR estimates:
- Negative: Non-GAAP EPS, $ of -1.64 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -25.35 <= 2.35
- Negative: negative Net income
Short-term AVIR quotes
Long-term AVIR plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $351.37MM | $0.00MM | $0.00MM |
| Operating Expenses | $212.99MM | $130.65MM | $164.16MM |
| Operating Income | $138.38MM | $-130.65MM | $-164.16MM |
| Non-Operating Income | $0.21MM | $11.15MM | $29.22MM |
| R&D Expense | $167.21MM | $81.94MM | $132.84MM |
| Income(Loss) | $138.59MM | $-119.50MM | $-134.94MM |
| Taxes | $17.40MM | $-3.59MM | $1.02MM |
| Profit(Loss) | $121.19MM | $-115.91MM | $-135.96MM |
| Stockholders Equity | $710.08MM | $640.57MM | $555.19MM |
| Assets | $772.89MM | $666.71MM | $594.97MM |
| Operating Cash Flow | $-87.00MM | $-120.98MM | $-85.39MM |
| Capital expenditure | $0.00MM | $1.94MM | $0.00MM |
| Investing Cash Flow | $-0.00MM | $-455.41MM | $40.30MM |
| Financing Cash Flow | $1.47MM | $0.37MM | $0.26MM |
| Earnings Per Share* | $1.46 | $-1.39 | $-1.63 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.